Cholesterol management is an important factor in the modification of primary and secondary cardiovascular events. Guidelines emphasize incorporation of appropriate medication therapy and lifestyle adjustments to reduce low-density lipoprotein cholesterol (LDL-C) for cardiovascular disease (CVD) risk reduction. Of note, studies and nation-wide statistics indicate many patients do not achieve their LDL-C goals. Eliminating barriers and challenges associated with cholesterol management will allow patients to reach prespecified goals for CVD risk reduction. As the nation transitions to covering more individuals, the need for additional health care providers is evident. Pharmacists are accessible and knowledgeable health care contributors who can assist in optimizing patient outcomes. This article discusses the pharmacist’s role in addressing challenges and barriers in cholesterol management.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285
(19):2486–2497.
2.
GoASMozaffarianDRogerVL. Heart disease and stroke statistics—2014 update a report from the American Heart Association. Circulation. 2014;129(3):e28–e292. doi:10.1161/01.cir.0000441139.02102.80.
WiegandPMcCombsJSWangJJ. Factors of hyperlipidemia medication adherence in a nationwide health plan. Am J Manag Care. 2012;18
(4):193–199.
5.
PeetersAMamunAAWillekensF. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J. 2002;23
(6):458–466. doi:10.1053/euhj.2001.2838.
6.
SchweikertBHungerMMeisingerC. Quality of life several years after myocardial infarction: comparing the MONICA/KORA registry to the general population. Eur Heart J. 2009;30
(4):436–443. doi:10.1093/eurheartj/ehn509.
7.
TengsTOLinTH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21
(3):191–200.
8.
PignoneMEarnshawSTiceJA. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost–utility analysis. Ann Intern Med. 2006;144
(5):326–336. doi:10.7326/0003-4819-144-5-200603070-00007.
9.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
10.
ShepherdJCobbeSMFordI. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333
(20):1301–1308. doi:10.1056/NEJM199511163332001.
11.
DownsJRClearfieldMWeisS. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279
(20):1615–1622. doi:10.1001/jama.279.20.1615.
12.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7–22. doi:10.1016/S0140-6736(02)09327-3.
13.
AlmutiKRimawiRSpevackD. Effects of statins beyond lipid lowering: Potential for clinical benefits. Int J Cardiol. 2006;109
(1):7–15. doi:10.1016/j.ijcard.2005.05.056.
14.
DonaldsonAAndrusM. Pharmacist-run lipid management program in rural Alabama. Am J Health Syst Pharm. 2004;61
(5):493–497.
15.
StoneNJRobinsonJLichtensteinAH. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129
(25 suppl 2):S1–S45. doi:10.1161/01.cir.0000437738.63853.7a.
16.
OlsonKLRasmussenJSandhoffBG. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med. 2005;165
(1):49–54. doi:10.1001/archinte.165.1.49.
17.
McConnellDKJDenhamAMOlsonKL. Pharmacist-Led interventions for the management of cardiovascular disease. Dis Manag Health Outcomes. 2008;16
(3):131–144. doi:10.2165/00115677-200816030-00001.
18.
StrakaRJTaheriRCooperSL. Achieving Cholesterol Target in a Managed Care Organization (ACTION) trial. Pharmacother J Hum Pharmacol Drug Ther. 2005;25(3):360–371. doi:10.1592/phco.25.3.360.61601.
19.
MannuGSZamanMJSGuptaA. Evidence of lifestyle modification in the management of hypercholesterolemia. Curr Cardiol Rev. 2013;9
(1):2–14.
20.
KingACHaskellWLYoungDR. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation. 1995;91
(10):2596–2604. doi:10.1161/01.CIR.91.10.2596.
21.
DuncanGEAntonSDSydemanSJ. Prescribing exercise at varied levels of intensity and frequency: a randomized trial. Arch Intern Med. 2005;165
(20):2362–2369. doi:10.1001/archinte.165.20.2362.
PlatJMensinkRP. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol. 2005;96
(1 suppl):15–22. doi:10.1016/j.amjcard.2005.03.015.
24.
KellyRB. Diet and exercise in the management of hyperlipidemia. Am Fam Physician. 2010;81
(9):1097–1102.
25.
Van HornLMcCoinMKris-EthertonPM. The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc. 2008;108
(2):287–331. doi:10.1016/j.jada.2007.10.050.
26.
MakiKCLawlessALReevesMS. Lipid-altering effects of a dietary supplement tablet containing free plant sterols and stanols in men and women with primary hypercholesterolaemia: a randomized, placebo-controlled crossover trial. Int J Food Sci Nutr. 2012;63
(4):476–482. doi:10.3109/09637486.2011.636345.
27.
SchultzABChenC-YBurtonWN. The burden and management of dyslipidemia: practical issues. Popul Health Manag. 2012;15
(5):302–308. doi:10.1089/pop.2011.0081.
28.
MannDMAllegranteJPNatarajanS. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007;21
(4):311–316. doi:10.1007/s10557-007-6040-4.
MolokhiaMMcKeiguePCurcinV. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. PLoS One. 2008;3
(6):e2522. doi:10.1371/journal.pone.0002522.
BitzurRCohenHKamariY. Intolerance to statins: mechanisms and management. Diabetes Care. 2013;36
(suppl 2):S325–S330. doi:10.2337/dcS13-2038.
37.
JacobsonTA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83
(6):687–700. doi:10.4065/83.6.687.
38.
SteinEABallantyneCMWindlerE. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008;101
(4):490–496. doi:10.1016/j.amjcard.2007.09.099.
39.
BettermannKArnoldAMWilliamsonJ. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis. 2012;21
(6):436–444. doi:10.1016/j.jstrokecerebrovasdis.2010.11.002.
40.
WilkinsonMJLaffinLJDavidsonMH. Overcoming toxicity and side-effects of lipid lowering therapies. Best Pract Res Clin Endocrinol Metab. 2014;28
(3):439–452. doi:10.1016/j.beem.2014.01.006.
41.
GeberJParraDBeckeyNPKormanL. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy. 2002;22:738–747.
42.
BottorffMB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97
(8 suppl 1):S27–S31. doi:10.1016/j.amjcard.2005.12.007.
43.
NessGCZhaoZLopezD. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys. 1996;325
(2):242–248. doi:10.1006/abbi.1996.0030.
44.
GohIXWHowCHTavintharanS. Cytochrome P450 drug interactions with statin therapy. Singapore Med J. 2013;54
(3):131–135.
45.
HanlonJTLindbladCIGraySL. Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults?Am J Geriatr Pharmacother. 2004;2
(1):3–13. doi:10.1016/S1543-5946(04)90002-5.
46.
SimonsLALevisGSimonsJ. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164
(4):208–211.
47.
BergJSDischlerJWagnerDJ. Medication compliance: a healthcare problem. Ann Pharmacother. 1993;27
(9 Suppl): S1–24.
48.
YeXGrossCRSchommerJ. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29
(12):2748–2757. doi:10.1016/j.clinthera.2007.12.022.
49.
ItoMK. Role of the pharmacist in establishing lipid intervention programs. Pharmacotherapy. 2003;23(9 pt 2):41S–47S. doi:10.1592/phco.23.11.41S.32712.
50.
KiortsisDNGiralPBruckertE. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25
(6):445–451. doi:10.1046/j.1365-2710.2000.00315.x.
51.
LalondeLHudonEGoudreauJ. Physician–pharmacist collaborative care in dyslipidemia management: the perception of clinicians and patients. Res Soc Adm Pharm. 2011;7
(3):233–245. doi:10.1016/j.sapharm.2010.05.003.
52.
BaesslerAFischerMHufV. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol. 2005;101
(2):293–298. doi:10.1016/j.ijcard.2004.03.053.
53.
PearsonTALauroraIChuH. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160
(4):459–467.
54.
JonesPHMcKenneyJMKaralisDG. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J. 2005;149
(1):e1–e8. doi:10.1016/j.ahj.2004.07.025.
